Rocket Pharmaceuticals, Inc.
RCKT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $171 | $186 | $166 | $125 |
| G&A Expenses | $102 | $73 | $59 | $42 |
| SG&A Expenses | $102 | $73 | $59 | $42 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $273 | $260 | $224 | $167 |
| Operating Income | -$273 | -$260 | -$224 | -$167 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $14 | $14 | $2 | -$2 |
| Pre-Tax Income | -$259 | -$246 | -$222 | -$169 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$259 | -$246 | -$222 | -$169 |
| % Margin | – | – | – | – |
| EPS | -2.73 | -2.92 | -3.26 | -2.68 |
| % Growth | 6.5% | 10.4% | -21.6% | – |
| EPS Diluted | -2.73 | -2.92 | -3.26 | -2.68 |
| Weighted Avg Shares Out | 95 | 84 | 68 | 63 |
| Weighted Avg Shares Out Dil | 95 | 84 | 68 | 63 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18 | $16 | $4 | $3 |
| Interest Expense | $2 | $2 | $2 | $6 |
| Depreciation & Amortization | $9 | $7 | $6 | $5 |
| EBITDA | -$247 | -$237 | -$214 | -$158 |
| % Margin | – | – | – | – |